1) The intramuscular administration of amikacin to mature rabbits at a dose of 40 mg/kg resulted in a peak serum concentration of 38.0 μg/ml at 30 minutes after dosing and in a peak aqueous humor concentration of 4.2 μg/ml at 1 hour after dosing.
2) The subconjunctival administration of amikacin to mature rabbits at a dose of 10 mg (0.2 ml) resulted in a peak aqueous humor concentration of 5.7 μg/ml at 1 hour after dosing, but relatively high concentrations were kept for hours in the posterior chamber where an aqueous humor concentration of 11.0 μg/ml was observed 4 hours after dosing.
3) In healthy adults, the intramuscular administration of amikacin at a dose of 100 mg resulted in a peak serum concentration of 11.0 μg/ml at 30 minutes after dosing.
4) Amikacin was administered intramuscularly to preoperative patients with cataract at a dose of 100 mg, in order to determine their aqueous humor concentrations. Most of them were less than 0.3μg/ml, but an aqueous humor concentration of 6.0 μg/ml was observed in a patient with past historyof iritus.
5) Clinically, amikacin was administered to 13 patients consisting of external hordeolum, acute dacriocystitis and endophthalmitis. Clinical response was excellent in 2, good in 10 and unknown in 2, its effectiveness rate being 92%.
No particular side-effects were observed.
